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1.1. Need for developing case deﬁnitions and guidelines for data
collection, analysis, and presentation for pathways to preterm
birth as an adverse event following immunization
While immunizations confer protection against speciﬁc sub-
types of infections, it is important to determine whether these
interventions contribute to adverse maternal or neonatal out-
comes in pregnancy. In particular, understanding the risk/beneﬁt of
immunizations with respect to pathways resulting in preterm birth
is of particular interest. Preterm birth results from a variety of path-
ways ranging from idiopathic to spontaneous etiologies. Because
there is a diverse spectrum of possible causes of preterm birth, it is
Y license (http://creativecommons.org/licenses/by/4.0/).
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mportant to determine whether some of the pathways to preterm
irth can be activated by interventions, including immunizations.
The pathophysiology and pathways related to preterm birth rep-
esent diverse and complex processes. A critical principle is that
pontaneous preterm births result from a spectrum of patholog-
cal processes that are initiated by speciﬁc molecular pathways,
onverging into a common pathway [1]. These molecular mecha-
isms are inﬂuenced by genetic, epigenetic, biological, behavioral,
ocial, clinical, and environmental risk factors [1]. Different insults,
uch as stress, inﬂammation or infection, hemorrhage, uterine
istention, and immune dysregulation can lead to uterine decid-
al and fetal membrane activation, which stimulate release of
rostaglandins, cytokines, and matrix metalloproteinases that in
urn lead to uterine contractions, cervical ripening, membrane rup-
ure and subsequently, preterm birth [1]. In essence, it appears
hat the processes whereby term labor is initiated are implicated
n preterm birth as well, with an important distinction being that
erm parturition results from physiologic activation of the compo-
ents of the common pathway, while preterm labor arises from
athological processes that activate one or more of those compo-
ents [1]. It is hypothesized that before 32 weeks gestation, the
nitiation of pathways to preterm birth requires a stronger stim-
lus than after 32 weeks, as later in the third trimester there
s normal physiologic preparation of the uterus and cervix for
elivery [1].
While preterm birth is being formally deﬁned by another
righton Collaboration working group and that deﬁnition will be
ncorporated into this document, the purpose of this exercise is to
evelop case deﬁnitions and guidelines for data collection, analysis,
nd presentation for the pathways to preterm birth. The etiolo-
ies of preterm birth can be grouped into four pathways that are
onsidered the underlying events leading to preterm birth; they
nclude: (1) premature preterm rupture of membranes (PPROM),
2) spontaneous preterm labor (PTL), (3) insufﬁcient cervix (IC),
nd (4) provider-initiated preterm birth (PIPTB). Of note, the ﬁrst
hree pathways are spontaneously occurring processes, while the
ourth occurs when a decision is reached between a patient and her
rovider that iatrogenic initiation of labor is required for the health
f the fetus, mother, or both. These four pathways are the adverse
vents of interest in this document, which will focus primarily on
ow researchers, in the context of vaccine trials, can determine that
ne of these four pathways has been activated, or an adverse event
as occurred.
The diverse array of etiologies, coupled with obscured and/or
verlapping clinical and scientiﬁc deﬁnitions has led to inconsistent
eﬁnitions of pathways leading to preterm birth. Moving toward
 consensus deﬁnition is critical for the purposes of monitoring
dverse events in vaccine trials and to standardize terminology for
mproved data collection. Issues related to deﬁning and classifying
reterm birth include: relying on gestational age estimates based
n a variety of approaches and validity, distinguishing between
linical versus etiologic phenotypes of preterm birth, considering
hether to include or exclude multi-fetal gestations or stillborn
nfants, and deciding how to separate or combine different path-
ays to preterm birth [2]. Given that the term pathways to preterm
irth has met  with such difﬁculty in deﬁnition and classiﬁca-
ion previously, it is a crucial adverse outcome for the Brighton
ollaboration to clarify for use in the context of vaccine related
esearch.
Literature searches related to immunization in pregnancy were
erformed to identify existing deﬁnitions and contributing factors
or premature preterm rupture of membranes, preterm labor, insuf-
094cient cervix, and provider-initiated preterm delivery; the four
athways to preterm birth. For premature preterm rupture of mem-
ranes, no data were published on the incidence of this outcome
n association with immunizations in pregnancy. The same wase  (2016) –
true for insufﬁcient cervix and provider-initiated preterm delivery;
no published incidence of these outcomes related to immuniza-
tion in pregnancy were available, even when similar terms were
included in the search (incompetent cervix, iatrogenic preterm
delivery/birth). In the case of preterm labor, while almost 100
studies were found based on the search terms preterm labor and
immunization, only three of the articles mentioned preterm labor
in the text of the articles, with only one reporting the incidence
of preterm labor in the setting of an immunization. That paper
reported that following administration of inﬂuenza A (H1N1) 2009
monovalent vaccine, 294 adverse events in pregnant women  were
reported to the Vaccine Adverse Event Reporting System; two
women experienced preterm labor, or 1% of the immunized pop-
ulation in the United States [3]. There was no description of the
deﬁnition used for preterm labor in this study or the long-term out-
comes of those pregnancies; overall, however, it was determined
that preterm labor was not likely due to the immunization itself
[3].
Existing case deﬁnitions for the term, ‘pathways to preterm
birth’, do not exist. Description of preterm birth as a syndrome,
however, is a common ﬁnding, and attempts have been made
at standardizing the pathways to preterm birth [1,2]. One clas-
siﬁcation system published in the American Journal of Obstetrics
and Gynecology proposed a method based on clinical phenotypes
deﬁned by characteristics of the mother, fetus, placenta, signs of
parturition, and the pathway to delivery [2]. This methodology
involves detailed information on maternal, fetal, and placental con-
ditions as well as information regarding the initiation of parturition
and the pathway to delivery [2]. Under this system a particular
patient may  fall into one or more of the phenotypes allowing her
case to be deﬁned by all relevant conditions, instead of forced into
one strictly deﬁned pathway [2]. For example, maternal condi-
tions include such clinical scenarios as intra-amniotic infection,
trauma, pre-eclampsia/eclampsia, and uterine rupture [2]. Fetal
and placental conditions as well as symptoms of parturition and
the pathway to delivery also are listed in the document [2]. While
this methodology has not been validated, the authors suggest that it
be piloted in a population and evaluated for utility [2]. This method-
ology offers a very ﬂexible approach to the concept of classifying
pathways to preterm birth, but for the purposes of this docu-
ment, the goal was to develop a better-deﬁned set of pathways
to preterm birth that can be measured and documented in vaccine
research.
Each of the four pathways to preterm birth as presented in
this document do have existing case deﬁnitions in the literature.
For example, premature preterm rupture of membranes has been
deﬁned as, “rupture of the fetal membranes before term and out-
side of the context of labor” [4]. Preterm labor has previously been
deﬁned as “a syndrome attributable to multiple pathologic pro-
cesses leading to uterine contractions that cause cervical change
before term” [6]. Insufﬁcient cervix has been deﬁned as, “the inabil-
ity of the uterine cervix to retain a pregnancy in the absence of the
signs and symptoms of clinical contractions, or labor, or both in the
second trimester” [7]. For the ﬁnal pathway to preterm birth, a def-
inition published regarding what was termed ‘iatrogenic preterm
birth’ (which for the purposes of this document has been called,
‘provider-initiated preterm birth’) is, “nonspontaneous delivery
before term” [8]. While some of these deﬁnitions are more spe-
ciﬁc than others, they are overall too general for use as outcomes
of interest in vaccine-speciﬁc and other research, and would ben-
eﬁt from further development as broadly applicable and clinically
speciﬁc deﬁnitions. As mentioned, the term ‘pathways to preterm
birth’ suffers from the lack of a formal deﬁnition and represents a
missed opportunity, as data comparability across trials or surveil-
34 6093 6101lance systems would facilitate data interpretation and promote the
scientiﬁc understanding of the event.
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.2. Methods for the development of the case deﬁnition and
uidelines for data collection, analysis, and presentation for
athways to preterm birth as an adverse events following
mmunization
Following the process described on the Brighton Collabora-
ion Website http://www.brightoncollaboration.org/internet/en/
ndex/process.html, the Brighton Collaboration Pathways to Preterm
irth Working Group was formed in 2015 and included members
rom clinical, academic, public health, and industry backgrounds.
he composition of the working and reference group as well
s results of the web-based survey completed by the reference
roup with subsequent discussions in the working group can
e viewed at: http://www.brightoncollaboration.org/internet/en/
ndex/working groups.html.
To guide the decision-making for the case deﬁnition and guide-
ines, a literature search was performed using Medline, Embase and
he Cochrane Libraries, including the terms: premature preterm
upture of membranes, preterm labor, insufﬁcient or incompetent
ervix, and immunization. The search resulted in the identiﬁcation
f 37 references. All abstracts were screened for possible reports
f initiation of the pathways to preterm birth following immuniza-
ion. All articles with potentially relevant material were reviewed
n more detail, in order to identify studies using case deﬁnitions or,
n their absence, providing clinical descriptions of the case mate-
ial. This review resulted in a detailed summary of three articles,
ncluding information on the study type, the vaccine, the diagnos-
ic criteria or case deﬁnition put forth, the time interval since time
f immunization, and any other symptoms. As such, other literature
n the pathways to preterm birth and immunizations in pregnancy,
n general, were made available to working group members, which
ncluded 28 papers.
.3. Rationale for selected decisions about the case deﬁnition of
athways to preterm birth as an adverse event following
mmunization
.3.1. The term ‘Pathways to preterm birth’
The decision to focus on individual pathways to preterm birth
s opposed to preterm labor alone was based on the expecta-
ion that immunizations may  have pathway dependent effects,
nd that there is a clinical need to understand how immunization
ay  inﬂuence the occurrence of an outcome. Addressing the clas-
iﬁcation of preterm birth or delineation of pathways to preterm
irth approaches the question why a preterm birth occurred in the
ost comprehensive manner possible, addressing a topic that has
chieved little consensus in the literature.
.3.2. The four speciﬁc pathways to preterm birth and why they
ere chosen for inclusion
Preterm birth is a complex syndrome that more easily deﬁes
eﬁnitional terms than conforms to them. Preterm birth is the
nly healthcare concept deﬁned by an arbitrary time point rather
han by a speciﬁc etiology or pathophysiology [2]. In the clinical
ontext, and especially in the context of vaccine research, provid-
ng guidance regarding pathways to preterm birth will improve
ata comparability and interpretation, and as a result, improve
ur understanding of preterm birth and its etiologies. As such,
he spontaneous preterm births were divided into the broadest
hree pathways that would maintain simplicity and clarity in
he deﬁnition while still being comprehensive. These include (1)
remature preterm rupture of membranes, (2) preterm labor, and
3) insufﬁcient cervix. Authors have previously suggested other
linical classiﬁcation methods, but generally those pathways can
e combined into the aforementioned three pathways without any
igniﬁcant loss of speciﬁcity in determination of the correcte  (2016) –  
deﬁnitional pathway. The ﬁnal pathway represents non-
spontaneous deliveries, and is termed (4) provider-initiated
preterm birth.
1.3.3. Classic features of pathways
1.3.3.1. Premature preterm rupture of membranes. The term ‘fetal
membranes’, or ‘membranes’, which are subject to rupture or
tear either spontaneously or artiﬁcially during labor, refers to
the chorion and amnion, two separate but juxtaposed layers that
enclose the amniotic cavity [4]. These membranes function to con-
tain and regulate amniotic ﬂuid volume around the fetus, transport
molecules selectively, and provide a barrier function to vaginal ﬂora
[4]. In 1–2% of pregnancies, membrane rupture preterm and out-
side the context of preterm labor, leads to preterm birth (about one
third of all preterm births) and subsequent maternal and neonatal
morbidity and mortality from infection and neonatal complica-
tions of prematurity [4]. Clinical conditions associated with PPROM
include infection and/or inﬂammation, abruption, uterine over-
distention (from multiple gestation or polyhydramnios), genetic
predispositions, and tobacco use [4]. Molecular pathways impli-
cated in PPROM include activation of matrix metalloproteinases,
cytokines, apoptosis, and oxidative stress as the primary mecha-
nisms leading to premature degradation of the fetal membranes
[4,5]. This is separate and distinct from rupture of membranes that
may  occur during the term labor process whereby biomechanical
stress and the molecular pathways leading to membrane degrada-
tion are activated physiologically, as opposed to in the setting of
PPROM, where they are activated pathologically and outside the
context of labor.
1.3.3.2. Preterm labor. Much like PTB and PPROM, PTL is also a syn-
drome associated with multiple mechanisms of disease. Analogous
to PPROM, PTL is not simply activation of the mechanisms leading to
labor in the preterm setting; rather, labor at term is the physiologic
activation of parturition while preterm labor is the result of several
possible disease processes and external stimuli leading to patho-
logic activation of the component pathways leading to labor and
delivery [6]. Term labor is characterized by increased myometrial
contractility, cervical dilation, and rupture of the chorioamni-
otic membranes, which are associated with a change in nuclear
progesterone receptor isoforms, an increase in estrogen receptor
signaling, changes in cervical extracellular matrix proteins, and
decidual and membrane activation, which facilitate separation of
the fetal membranes and placenta from the uterus [6]. Spontaneous
preterm labor is thought to occur as a result of multiple possible
disease mechanisms, including infection, vascular disorders, decid-
ual senescence, uterine over-distention, decline in progesterone
action, breakdown of maternal-fetal immune tolerance, thyroid
autoimmunity, and stress, among other unknown etiologies [6].
Clinically, however, in terms of the ﬁnal common pathway of labor,
gestational age may  be the only notable difference in settings where
PTB is occurring.
1.3.3.3. Insufﬁcient cervix. In comparison to PPROM and PTL, little
is known about the pathophysiology of insufﬁcient cervix. Much of
what is known about the condition is based on clinical research and
associated risk factors, but less is known about the science. Factors
that may  increase the risk of cervical insufﬁciency include cervical
trauma from prior surgery, such as cervical conization or loop elec-
trosurgical excision procedures, mechanical dilation of the cervix
during termination procedures, or a history of cervical laceration
during delivery or prolonged labor that may  damage the cervical
34 6093 6101 6095tissue, although data conﬁrming these associations are scant and
inconsistent [9]. Currently, the practice of screening for and predict-
ing which patients are at the greatest risk for cervical insufﬁciency
based on history and characteristics of the incident pregnancy is the
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tandard of care regarding prevention of preterm birth due to cer-
ical insufﬁciency; unfortunately, since the presentation is usually
ainless cervical dilation and subsequent delivery, this pathway is
ften at an advanced stage when discovered and difﬁcult, if not
mpossible, to treat effectively.
.3.3.4. Provider-initiated preterm birth. The global community has
ecome focused on preterm birth and the burden it places on
amilies, communities, countries, and healthcare systems. As such,
on-spontaneous preterm births, or those that occur as a result
f a healthcare provider’s decision to deliver as opposed to a
pontaneous process, have become a topic of particular interest
ecause if they are avoidable, their prevention could reduce pre-
aturity rates and complications. Review of the literature has
uggested that 28–40% of all preterm deliveries are provider-
nitiated, and that the incidence of such deliveries may  be on
he rise, especially in high-income countries (HIC) [10]. Common
ndications for provider-initiated preterm births include maternal
ndications such as: hypertensive disorders, cholestasis of preg-
ancy, pre-existing maternal medical conditions; fetal indications,
hat include: anemia, alloimmunization, infection, fetomaternal
emorrhage, intrauterine growth restriction, multiple gestation
ith discordant fetal growth, monoamniotic twins, or twin-to-twin
ransfusion syndrome; and pregnancy complications, such as: pla-
ental implantation abnormalities, placental abruption, and prior
terine surgery and risk of uterine rupture [10]. Of note, the indi-
ations cited for some provider-initiated preterm births have been
etermined to be non-evidence-based (57% in one study), which
aises concern that there is a preventable and unnecessary burden
f provider-initiated preterm birth that currently exists [8].
.3.4. Standardization of diagnostics that are part of pathways
eﬁnitions
Generally, diagnostics most frequently used in the levels of
ertainty for deﬁnitional inclusion of an event in one of the path-
ays to preterm birth include ultrasound and clinical evaluation.
ltrasound utilization includes determination of the amniotic ﬂuid
ndex as part of level 1 of certainty for PPROM, and transvaginal
ervical length and dilation assessment as part of the deﬁnitions of
evel 1 of diagnostic certainty of preterm labor, and level 1 of diag-
ostic certainty for insufﬁcient cervix. Neither amniotic ﬂuid index
or cervical length/dilation assessment is of a particularly high level
f difﬁculty for a routinely trained ultrasound technician in a set-
ing where ultrasound is commonly used and regularly available.
herefore, routine training in both abdominal and transvaginal
echniques should constitute standardization of ultrasound use in
etting where ultrasound is highly utilized.
Clinical examination presents a challenge to standardization
s it is inherently a more subjective measure and may  reﬂect a
linician’s experience and level of training. For PPROM, clinical eval-
ation requires the ability to collect a history, visualize leakage of
uid, and determine arborization of cervical ﬂuid on microscopy.
or PTL, clinical skills are required to quantify uterine contractions,
etermine rupture of membranes, and assess cervical effacement
nd dilation by digital examination. The diagnostic certainty of
nsufﬁcient cervix also requires clinical determination of cervical
ffacement and dilation by digital examination and ability to collect
 detailed obstetric history. The ﬁnal pathway, provider-initiated
reterm birth, does not require any physical clinical skills, but does
equire the ability to collect an obstetric history with attention to
he nuance of determining whether a preterm birth was  facilitated
y a provider. There is no method to standardize these clinical skills;
096t is the hope that with high quality training and experience similar
utcomes would be achieved between providers, but standardiza-
ion of these clinical diagnostics are likely to exhibit inter-provider
ariability.e  (2016) 
A number of commercially available products exist for diagnos-
ing PPROM by testing vaginal discharge for amniotic ﬂuid. These are
listed as part of level 1 of diagnostic certainty for PPROM. There is
no need for standardization across settings regarding which prod-
uct to use, because while some products have better sensitivity and
speciﬁcity than others, this is only one component of the deﬁnition,
and in 90% of cases PPROM can be determined by history and gross
evidence of rupture of membranes [11]. Using any one of the com-
mercially available products should constitute standardization of
diagnostic method in this circumstance.
1.3.5. Settings where diagnostics may not be available
Preterm birth rates are highest in low and middle-income
countries (LMIC) [12]. These are also the settings with the least
resources where it may  be difﬁcult to achieve level 1 of diagnostic
certainty because of difﬁculty with access to ultrasound or com-
mercial amniotic ﬂuid detection products, or because clinicians are
overall less trained and/or less experienced. Overall, however, the
Working Group believes that high quality data can still be collected
in these settings based on levels 2 and 3 of diagnostic certainty.
However, it should be noted that all levels of diagnostic certainty
are considered acceptable depending on the availability of diagnos-
tic tools in each site.
1.3.6. Role of risk factors
Multiple risk factors increase a woman’s risk of preterm birth
outside the context of vaccine research, and should be taken into
account when outcomes data are analyzed in the setting of an
immunization trial in pregnancy. For example, in the United States,
race and socioecomic status have been implicated as risk factors
of preterm birth, with race as an independent risk factor when
studies control for socioeconomic status [1]. International litera-
ture has indicated there is evidence for an increased risk of PTB
for women  with the following characteristics: history or family
history of prior PTB, substance and tobacco use, advanced mater-
nal age or teen pregnancy, multiple gestation and use of advanced
reproductive technology, low socioeconomic status, poor prenatal
care, low BMI, infections (bacterial vaginosis), poor nutrition and
inappropriate weight gain during pregnancy, short interpregnancy
interval, maternal hyperglycemia, persistent malarial infection,
anemia (including folate deﬁciency), domestic violence, maternal
height <145 cm,  and pre-eclampsia [1]. While the pathophysiology
and relationship between these risk factors and preterm birth is not
always well understood, it is important to consider when analyzing
data related to pathways to preterm birth.
1.3.7. Formulating a case deﬁnition that reﬂects diagnostic
certainty: weighing speciﬁcity versus sensitivity
The case deﬁnition for pathways to preterm birth has been for-
mulated such that the Level 1 deﬁnition is highly speciﬁc for the
condition. As maximum speciﬁcity normally implies a loss of sen-
sitivity, two  additional diagnostic levels have been included in the
deﬁnition, offering a stepwise increase of sensitivity from Level 1
down to Level 3, while retaining an acceptable level of speciﬁcity at
all levels. In this way, it is hoped that all possible cases of pathways
to preterm birth can be captured.
It needs to be re-emphasized that the grading of deﬁnition lev-
els is entirely about diagnostic certainty, not clinical severity of
an event. Thus, a clinically very severe event may  appropriately
be classiﬁed as Level 2 or 3 rather than Level 1 if it could reason-
34 6093–6101ably be of an etiology not related to a pathway leading to preterm
birth. Detailed information about the severity of the event should
additionally always be recorded, as speciﬁed by the data collection
guidelines.
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.3.8. The meaning of ‘sudden onset’ and ‘rapid progression’ in
he context of pathways to preterm birth
The term “sudden onset” refers to an event that occurred unex-
ectedly and without warning leading to a marked change in a
ubject’s previously stable condition. The term “rapid progres-
ion” is a conventional clinical term. An exact timeframe should
ot be offered since it would have to refer to a wide range of
igns and symptoms without a scientiﬁc evidence base. Using an
rbitrarily restrictive set point might bias future data collection
nnecessarily.
.3.9. Timing post-immunization
Speciﬁc time frames for onset of symptoms following immu-
ization are not included because pathways to preterm birth are
ost often activated outside the controlled setting of a clini-
al trial or hospital. In some settings it may  be impossible to
btain a clear timeline of the event, particularly in less developed
r rural settings. In order to avoid selecting against such cases,
he Brighton Collaboration deﬁnition avoids setting arbitrary time
rames.
.3.10. Inﬂuence of treatment on fulﬁllment of case deﬁnition
The Working Group decided against using ‘treatment’ or ‘treat-
ent response’ toward fulﬁllment of the pathways to preterm birth
ase deﬁnition. A treatment response or its failure is not in itself
iagnostic, and may  depend on variables like clinical status, time
o treatment, and other clinical parameters. Hence, the levels of
iagnostic certainty deﬁnitions are designed to be broad enough to
nclude cases presenting differently due to appropriate and early
reatment initiation.
.4. Guidelines for data collection, analysis and presentation
The case deﬁnitions are accompanied by guidelines, which are
tructured according to the steps of conducting a clinical trial, i.e.
ata collection, analysis and presentation. Neither case deﬁnition
or guidelines are intended to guide or establish criteria for man-
gement of ill infants, children, or adults. Both were developed to
mprove data comparability.
.5. Periodic review
Similar to all Brighton Collaboration case deﬁnitions and guide-
ines, review of the deﬁnition with its guidelines is planned on a
egular basis (i.e. every three to ﬁve years) or more often if needed.
. Case deﬁnition of pathways to preterm birth
Pathways to preterm birth is a clinical syndrome characterized
y any one or some combination of the following four pathways:
Premature preterm rupture of membranes
Preterm labor
Insufﬁcient cervix
Provider-initiated preterm birth
For the purposes of presenting a case deﬁnition of pathways to
reterm birth, each pathway will be considered individually and
ubject to all levels of diagnostic certainty.
.1. Case deﬁnition of premature preterm rupture of membranes
s a pathway to preterm birthe  (2016) –  
For all levels of diagnostic certainty:
• Patient is determined to be preterm as deﬁned by the Brighton
Collaboration deﬁnition
• On presentation, patient is determined to not be in preterm labor,
having ≤4 contractions per hour documented clinically or on
tocodynometer, with <2 cm cervical dilation (greater than 4 con-
tractions per hour would qualify the patient as having preterm
labor)
• Fluid can be noted to be clear, blood-tinged, meconium-tinged
(fetal stool), purulent-tinged (yellowish, suggesting infection)
Level 1 Diagnostic Certainty:
1. Clinical history of rupture of membranes AND
2. Visible leakage of ﬂuid on vaginal speculum exam AND
3. Visible arborization (ferning) on microscopy of amniotic ﬂuid OR
4. Ultrasound with oligohydramnios (AFI <5 or MVP  <2) AND
5. Documented membrane rupture by a diagnostic test (one of the
below options)
a. Positive intra-amniotic dye-injection method
b. Positive result on amniotic ﬂuid alpha-fetoprotein test kit
c. Amniotic ﬂuid pH measurement (nitrazine paper test)
d. Amniotic ﬂuid placental alpha macroglobulin-1 protein assay
(PAMG-1) test (AmniSure test)
e. Amniotic ﬂuid insulin-like growth factor binding protein
(IGFBP-1) test (Actim PROM test)
Level 2 Diagnostic Certainty:
1. Clinical history of rupture of membranes AND
2. Visible leakage of ﬂuid on vaginal speculum examination AND
3. Visible arborization (ferning) on microscopy of amniotic ﬂuid OR
document membrane rupture by a diagnostic test (one of those
listed above) OR
4. Ultrasound with oligohydramnios (AFI <5 or MVP  <2)
Level 3 Diagnostic Certainty:
1. Clinical history of rupture of membranes AND
2. Visible leakage of presumed amniotic ﬂuid; this may be on vagi-
nal speculum examination (pooling in vagina), on inspection of
the perineum (wet perineum due to leakage of ﬂuid from the
vagina), or ﬂuid soaked cloth/clothes/sanitary pad
2.2. Case deﬁnition of preterm labor as a pathway to preterm
birth
For all levels of diagnostic certainty:
• Patient is determined to be have delivered preterm as deﬁned by
the Brighton Collaboration deﬁnition
Level 1 Diagnostic Certainty:
1. On presentation, >4 documented uterine contractions per hour
as determined by a tocodynometer AND
2. Documented change in length or dilation of cervix by physical
examination or transvaginal ultrasound over a two  hour period,
with clinical criteria for documenting cervical change by exam
including:
34 6093 6101 6097a. Cervical dilation 2 cm or greater at the internal os by digital
examination
b. Cervical length of 1 cm or less by digital examination
c. 50% or greater effacement by digital examination
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Level 2 Diagnostic Certainty:
. Greater than 4 uterine contractions per hour as determined by a
tocodynometer or clinical assessment AND
. Documented change in length or dilation of cervix by physical
examination, with clinical criteria including:
a. Cervical dilation 2 cm or greater at the internal os by digital
examination
b. Cervical length of 1 cm or less by digital examination
c. 50% or greater effacement by digital examination
Level 3 Diagnostic Certainty:
. Greater than 4 documented uterine contractions per hour deter-
mined by clinical assessment AND
. Documented change in cervical examination (change in dilation
or effacement) over a two hour period
.3. Case deﬁnition of insufﬁcient cervix as a pathway to preterm
irth
For all levels of diagnostic certainty:
Patient is determined to be ≥16 weeks and <24 weeks gestation
as deﬁned by the Brighton Collaboration deﬁnitions of gestational
age
Patient is determined to have advanced cervical dilation (>2 cm)
resulting in either treatment with a cerclage (cervical stitch) or
preterm delivery
Patient is determined to not be in preterm labor, having ≤4 con-
tractions per hour documented clinically or on tocodynometer
(with anything >4 contractions per hour falling into the category
of preterm labor)
Level 1 Diagnostic Certainty:
. Internal cervical os dilation (>2 cm)  with ≤4 contractions/h, as
determined by transvaginal ultrasound AND digital examination
Level 2 Diagnostic Certainty:
. Internal cervical os dilation (>2 cm)  with ≤4 contractions/h, as
determined by digital examination
Level 3 Diagnostic Certainty:
. Patient reports fetal delivery without any painful contractions
. History excludes other causes of mid-trimester delivery
.4. Case deﬁnition of provider-initiated preterm delivery as a
athway to preterm birth
For all levels of diagnostic certainty:
Patient is determined to be preterm as deﬁned by the Brighton
Collaboration deﬁnition
Level 1 Diagnostic Certainty:
. Documentation in the healthcare record by a patient’s delivering
provider that there were no signs or symptoms of the sponta-
098neous onset of preterm labor AND
. Documentation in the healthcare record by a patient’s delivering
provider that the patient needed to undergo induction of labor
or cesarean delivery which led to the preterm deliverye  (2016) –
Level 2 Diagnostic Certainty:
1. From recall, delivering provider conﬁrms that there was an
absence of any signs or symptoms of the spontaneous onset of
preterm labor AND
2. Delivering provider reports from recall that he or she decided
that the patient needed to undergo induction of labor or cesarean
delivery
Level 3 Diagnostic Certainty:
1. From recall, patient conﬁrms that there was  an absence of any
signs or symptoms of the spontaneous onset of preterm labor
AND
2. Patient reports from recall that the healthcare provider indi-
cated that she needed to undergo induction of labor or cesarean
delivery
3. Guidelines for data collection, analysis and presentation
of pathways to preterm birth
It was  the consensus of the Brighton Collaboration Pathways to
Preterm Birth Working Group to recommend the following guide-
lines to enable meaningful and standardized collection, analysis,
and presentation of information about pathways to preterm birth.
However, implementation of all guidelines might not be possible
in all settings. The availability of information may  vary depending
upon resources, geographical region, and whether the source of
information is a prospective clinical trial, a post-marketing surveil-
lance or epidemiological study, or an individual report of a pathway
to preterm birth having occurred. Also, as explained in more detail
in the overview paper in this volume, these guidelines have been
developed by this working group for guidance only, and are not to
be considered a mandatory requirement for data collection, analy-
sis, or presentation.
3.1. Data collection
These guidelines represent a desirable standard for the col-
lection of data on availability following immunization to allow
for comparability of data, and are recommended as an addi-
tion to data collected for the speciﬁc study question and setting.
The guidelines are not intended to guide the primary repor-
ting of a pathway to yrs developing a data collection tool
based on these data collection guidelines also need to refer
to the criteria in the case deﬁnition, which are not repeated
in these guidelines. The Brighton Collaboration has devel-
oped guidelines for data collection https://brightoncollaboration.
org/public/resources/standards/guidelines.html; and data col-
lection forms https://brightoncollaboration.org/public/resources/
data-collection-forms.html.
Guidelines numbers below have been developed to address
data elements for the collection of adverse event information as
speciﬁed in general drug safety guidelines by the International
Conference on Harmonization of Technical Requirements for Reg-
istration of Pharmaceuticals for Human Use, and the form for
reporting of drug adverse events by the Council for International
Organizations of Medical Sciences [13,14]. These data elements
include an identiﬁable reporter and patient, one or more prior
immunizations, and a detailed description of the adverse event, in
this case, of a pathway to preterm birth as having occurred follow-
34 6093 6101ing immunization. The additional guidelines have been developed
as guidance for the collection of additional information to allow
for a more comprehensive understanding of pathways to preterm
birth that occur following immunization.
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i Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting2 and/or
diagnosing the pathways to preterm birth as speciﬁed by
country-speciﬁc data protection law.
(3) Name and contact information of the investigator responsible
for the subject, as applicable.
(4) Relation to the patient (e.g., immunizer [clinician, nurse],
family member [indicate relationship], other).
i Vaccinee/Control
1. Demographics
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(5) Case/study participant identiﬁers (e.g. ﬁrst name initial fol-
lowed by last name initial) or code (or in accordance with
country-speciﬁc data protection laws).
(6) Date of birth, age, and sex.
(7) For infants: Gestational age and birth weight.
2. Clinical and immunization history
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(8) Past medical history, including hospitalizations, under-
lying diseases/disorders, pre-immunization signs and
symptoms including identiﬁcation of indicators for, or the
absence of, a history of allergy to vaccines, vaccine com-
ponents or medications; food allergy; allergic rhinitis;
eczema; asthma.
(9) Any medication history (other than treatment for the
event described) prior to, during, and after immunization
including prescription and non-prescription medication
as well as medication or treatment with long half-life or
long term effect. (e.g. immunoglobulins, blood transfu-
sion and immunosuppressants).
(10) Immunization history (i.e. previous immunizations and
any adverse event following immunization (AEFI)), in
particular occurrence of a pathway to preterm birth as
having occurred after a previous immunization.
i Details of the immunization
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(11) Date and time of immunization(s).
(12) Description of vaccine(s) (name of vaccine, manufacturer,
lot number, dose (e.g. 0.25 mL,  0.5 mL,  etc.), diluent, and
number of dose if part of a series of immunizations against
the same disease).
(13) The anatomical sites (including left or right side) of all
immunizations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(14) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(15) Needle length and gauge.
 The adverse event
(16) For all cases at any level of diagnostic certainty and for
reported events with insufﬁcient evidence, the criteria ful-
ﬁlled to meet the case deﬁnition should be recorded.Speciﬁcally document:
2 If the reporting center is different from the vaccinating center, appropriate and
imely communication of the adverse event should occur.e  (2016) –  
(17) Clinical description of signs and symptoms of one of the
pathways to preterm birth, and if there was medical con-
ﬁrmation of the event (i.e. patient seen by physician).
(18) Date/time of onset,3 ﬁrst observation4 and diagnosis,5 end
of episode6 and ﬁnal outcome.7
(19) Concurrent signs, symptoms, and diseases.
(20) Measurement/testing
• Values and units of routinely measured parameters (e.g.
temperature, blood pressure) – in particular those indi-
cating the severity of the event;
• Method of measurement (e.g. type of thermometer, oral
or other route, duration of measurement, etc.);
• Results of laboratory examinations, surgical and/or patho-
logical ﬁndings and diagnoses if present.
(21) Treatment given for pathways to preterm birth, espe-
cially any antibiotics, corticosteroids, magnesium sulfate, or
tocolytics, with attention to which speciﬁc drugs were given
and in what dose. Mention should be made of whether a cer-
vical cerclage was placed in the case of insufﬁcient cervix as
a pathway to preterm birth and if so, which type.
(22) Outcome7 at last observation.
(23) Objective clinical evidence supporting classiﬁcation of the
event as “serious”.8
(24) Exposures other than the immunization 24 h before and
after immunization (e.g. food, environmental) considered
potentially relevant to the reported event.
v Miscellaneous/General
(25) The duration of surveillance for pathways to preterm birth
should be predeﬁned based on
• Biologic characteristics of the vaccine e.g. live attenuated
versus inactivated component vaccines;
• Biologic characteristics of the vaccine-targeted disease;
• Biologic characteristics of pathways to preterm birth
including patterns identiﬁed in previous trials (e.g. early-
phase trials); and
• Biologic characteristics of the vaccines (e.g. nutrition,
underlying disease like immunodepressing illness).
(26) The duration of follow-up reported during the surveillance
period should be predeﬁned likewise. It should aim to con-
tinue to resolution of the event.
(27) Methods of data collection should be consistent within and
between study groups, if applicable.
(28) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1–24.
(29) Investigators of patients with activation of one of the path-
ways to preterm birth should provide guidance to reporters
34 6093 6101 6099met  the case deﬁnition at any level.
6 The end of an episode is deﬁned as the time the event no longer meets the case
deﬁnition at the lowest level of the deﬁnition.
7 E.g. recovery to pre-immunization health status, spontaneous resolution, ther-
apeutic intervention, persistence of the event, sequelae, death.
8 An AEFI is deﬁned as serious by international standards if it meets one or
more of the following criteria: (1) it results in death, (2) is life-threatening, (3) it
requires inpatient hospitalization or results in prolongation of existing hospitaliza-
tion, (4) results in persistent or signiﬁcant disability/incapacity, (5) is a congenital
anomaly/birth defect, (6) is a medically important event or reaction.
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(30) Reports of activation of any of the four pathways to preterm
birth should be collected throughout the study period
regardless of the time elapsed between immunization and
the adverse event. If this is not feasible due to the study
design, the study periods during which safety data are being
collected should be clearly deﬁned.
.2. Data analysis
The following guidelines represent a desirable standard for anal-
sis of data on the occurrence of any of the pathways to preterm
irth (PPROM, PTL, IC, PIPTB) to allow for comparability of data, and
re recommended as an addition to data analyzed for the speciﬁc
tudy question and setting.
31) Reported events should be classiﬁed in one of the following
ﬁve categories including the three levels of diagnostic cer-
tainty. Events that meet the case deﬁnition should be classiﬁed
according to the levels of diagnostic certainty as speciﬁed in
the case deﬁnition. Events that do not meet the case deﬁnition
should be classiﬁed in the additional categories for analysis.
Event classiﬁcation in 5 categories9
Event meets case deﬁnition
(1) Level 1: Criteria as speciﬁed in the Pathways to Preterm Birth
case deﬁnition
(2) Level 2: Criteria as speciﬁed in the Pathways to Preterm Birth
case deﬁnition
(3) Level 3: Criteria as speciﬁed in the Pathways to Preterm Birth
case deﬁnition
Event does not meet case deﬁnitionAdditional categories for anal-
ysis
(4) Reported Pathways to Preterm Birth with insufﬁcient evidence
to meet the case deﬁnition10
(5) Not a case of Pathways to Preterm Birth
32) The interval between immunization and reported activation of
a pathway to preterm birth could be deﬁned as the date/time
of immunization to the date/time of onset3 of the ﬁrst symp-
toms and/or signs consistent with the deﬁnition. If few cases
are reported, the concrete time course could be analyzed for
each; for a large number of cases, data can be analyzed in the
following increments:
Subjects with activation of a pathway to preterm birth by inter-
al to presentation.
nterval Number
24 h
100–7 days
–30 days
1 days +
otal
9 To determine the appropriate category, the user should ﬁrst establish, whether
 reported event meets the criteria for the lowest applicable level of diagnostic
ertainty, e.g. Level three. If the lowest applicable level of diagnostic certainty of
he  deﬁnition is met, and there is evidence that the criteria of the next higher level
f  diagnostic certainty are met, the event should be classiﬁed in the next category.
his approach should be continued until the highest level of diagnostic certainty for
 given event could be determined. If the lowest level of the case deﬁnition is not
et, it should be ruled out that any of the higher levels of diagnostic certainty are
et  and the event should be classiﬁed in additional categories four or ﬁve.
10 If the evidence available for an event is insufﬁcient because information is
issing, such an event should be categorized as “Reported Cases of Activation of
 Pathway to Preterm Birth with insufﬁcient evidence to meet the case deﬁnition”.e  (2016) –
(33) The duration of a possible Pathways to Preterm Birth could be
analyzed as the interval between the date/time of onset2 of
the ﬁrst symptoms and/or signs consistent with the deﬁnition
and the end of episode6 and/or ﬁnal outcome7. Whatever start
and ending are used, they should be used consistently within
and across study groups.
(34) If more than one measurement of a particular criterion is taken
and recorded, the value corresponding to the greatest magni-
tude of the adverse experience could be used as the basis for
analysis. Analysis may  also include other characteristics like
qualitative patterns of criteria deﬁning the event.
(35) The distribution of data (as numerator and denominator data)
could be analyzed in predeﬁned increments (e.g. measured
values, times), where applicable. Increments speciﬁed above
should be used. When only a small number of cases is pre-
sented, the respective values or time course can be presented
individually.
(36) Data on Pathways to Preterm Birth obtained from sub-
jects receiving a vaccine should be compared with those
obtained from an appropriately selected and documented
control group(s) to assess background rates of hypersensitiv-
ity in non-exposed populations, and should be analyzed by
study arm and dose where possible, e.g. in prospective clinical
trials.
3.3. Data presentation
These guidelines represent a desirable standard for the pre-
sentation and publication of data on Pathways to Preterm Birth
following immunization to allow for comparability of data, and
are recommended as an addition to data presented for the spe-
ciﬁc study question and setting. Additionally, it is recommended to
refer to existing general guidelines for the presentation and pub-
lication of randomized controlled trials, systematic reviews, and
meta-analyses of observational studies in epidemiology (e.g. state-
ments of Consolidated Standards of Reporting Trials (CONSORT), of
Improving the quality of reports of meta-analyses of randomized
controlled trials (QUORUM), and of Meta-analysis Of Observational
Studies in Epidemiology (MOOSE), respectively) [15–17].
(37) All reported events of Pathways to Preterm Birth should be
presented according to the categories listed in guideline 31.
(38) Data on possible Pathways to Preterm Birth events should be
presented in accordance with data collection guidelines 1–24
and data analysis guidelines 31–36.
(39) Terms to describe Pathways to Preterm Birth such as “low-
grade”, “mild”, “moderate”, “high”, “severe” or “signiﬁcant”
are highly subjective, prone to wide interpretation, and should
be avoided, unless clearly deﬁned.
(40) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems
denominator data are usually not readily available, attempts
should be made to identify approximate denominators. The
source of the denominator data should be reported and
calculations of estimates be described (e.g. manufacturer data
like total doses distributed, reporting through Ministry of
Health, coverage/population based data, etc.).
(41) The incidence of cases in the study population should be pre-
sented and clearly identiﬁed as such in the text.
34 6093 6101(42) If the distribution of data is skewed, median and range are usu-
ally the more appropriate statistical descriptors than a mean.
However, the mean and standard deviation should also be
provided.
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43) Any publication of data on Pathways to Preterm Birth should
include a detailed description of the methods used for data
collection and analysis as possible. It is essential to specify:
• The study design;
• The method, frequency and duration of monitoring for acti-
vation of Pathways to Preterm Birth;
• The trial proﬁle, indicating participant ﬂow during a study
including drop-outs and withdrawals to indicate the size
and nature of the respective groups under investigation;
• The type of surveillance (e.g. passive or active surveillance);
• The characteristics of the surveillance system (e.g. popula-
tion served, mode of report solicitation);
• The search strategy in surveillance databases;
• Comparison group(s), if used for analysis;
• The instrument of data collection (e.g. standardized ques-
tionnaire, diary card, report form);
• Whether the day of immunization was considered “day one”
or “day zero” in the analysis;
• Whether the date of onset3 and/or the date of ﬁrst
observation4 and/or the date of diagnosis5 was used for anal-
ysis; and
• Use of this case deﬁnition for Pathways to Preterm Birth, in
the abstract or methods section of a publication11,12.
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